William Blair Investment Management LLC Increases Position in Mirum Pharmaceuticals, Inc. $MIRM

William Blair Investment Management LLC increased its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 7.5% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 336,701 shares of the company’s stock after buying an additional 23,442 shares during the quarter. William Blair Investment Management LLC’s holdings in Mirum Pharmaceuticals were worth $26,596,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Cullen Frost Bankers Inc. purchased a new stake in shares of Mirum Pharmaceuticals during the fourth quarter valued at $30,000. MCF Advisors LLC grew its holdings in shares of Mirum Pharmaceuticals by 76.4% during the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after buying an additional 185 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of Mirum Pharmaceuticals during the third quarter valued at $33,000. Quarry LP purchased a new stake in shares of Mirum Pharmaceuticals during the third quarter valued at $41,000. Finally, Comerica Bank grew its holdings in shares of Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after buying an additional 278 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on MIRM shares. TD Cowen boosted their price objective on shares of Mirum Pharmaceuticals from $125.00 to $145.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Raymond James Financial reissued a “strong-buy” rating and set a $165.00 price objective on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. Leerink Partners dropped their price objective on shares of Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating on the stock in a report on Thursday, February 26th. Citizens Jmp reissued a “market outperform” rating and set a $132.00 price objective on shares of Mirum Pharmaceuticals in a report on Tuesday, April 21st. Finally, Robert W. Baird boosted their price objective on shares of Mirum Pharmaceuticals from $112.00 to $129.00 and gave the company an “outperform” rating in a report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $137.08.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 40,985 shares of the company’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $91.98, for a total value of $3,769,800.30. Following the sale, the chief executive officer directly owned 194,309 shares of the company’s stock, valued at approximately $17,872,541.82. This represents a 17.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Eric Bjerkholt sold 7,287 shares of the company’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $91.98, for a total transaction of $670,258.26. Following the completion of the sale, the chief financial officer directly owned 49,788 shares in the company, valued at approximately $4,579,500.24. The trade was a 12.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 76,806 shares of company stock valued at $7,064,616 in the last 90 days. 14.36% of the stock is currently owned by insiders.

Mirum Pharmaceuticals Price Performance

NASDAQ:MIRM opened at $98.62 on Tuesday. Mirum Pharmaceuticals, Inc. has a one year low of $42.89 and a one year high of $114.99. The company has a debt-to-equity ratio of 1.28, a quick ratio of 1.99 and a current ratio of 2.09. The firm has a market cap of $6.01 billion, a price-to-earnings ratio of -7.25 and a beta of 0.52. The firm’s fifty day moving average is $96.38 and its two-hundred day moving average is $88.73.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($13.43) EPS for the quarter, missing the consensus estimate of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The business had revenue of $159.88 million during the quarter, compared to analysts’ expectations of $148.21 million. During the same period in the previous year, the company posted ($0.30) earnings per share. Mirum Pharmaceuticals’s revenue for the quarter was up 43.3% compared to the same quarter last year. Research analysts expect that Mirum Pharmaceuticals, Inc. will post -2.11 EPS for the current year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.